Axogen, Inc.
$37.23
▲
2.56%
2026-04-21 05:31:00
www.axogeninc.com
NCM: AXGN
Explore Axogen, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2 B
Current Price
$37.23
52W High / Low
$39.99 / $9.22
Stock P/E
—
Book Value
$2.73
Dividend Yield
—
ROCE
-3.96%
ROE
-13.49%
Face Value
—
EPS
$-0.34
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
622
Beta
0.98
Debt / Equity
55.5
Current Ratio
5.11
Quick Ratio
3.31
Forward P/E
42.13
Price / Sales
7.36
Enterprise Value
$1.69 B
EV / EBITDA
-1,932.08
EV / Revenue
7.5
Rating
Strong Buy
Target Price
$40.56
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Insulet Corporation | $193.4 | 55.6 | $13.48 B | — | 18.87% | 18.12% | $354.88 / $194.61 | $21.53 |
| 2. | Cytek Biosciences, Inc. | $4.57 | — | $592.62 M | — | -10.52% | -18.05% | $6.18 / $2.37 | $2.66 |
| 3. | MaxCyte, Inc. | $0.86 | — | $91.86 M | — | -24.06% | -23.63% | $2.96 / $0.64 | $1.61 |
| 4. | 20/20 Biolabs, Inc. | $1.71 | — | — | — | -253.94% | -5.03% | $50 / $1.51 | $0.01 |
| 5. | Intelligent Bio Solutions Inc. | $2.93 | — | $5.86 M | — | -359.62% | -1.5% | $24.9 / $2.42 | $8.96 |
| 6. | Myomo, Inc. | $0.9 | — | $34.65 M | — | -47.54% | -86.24% | $4.99 / $0.6 | $0.3 |
| 7. | Bioventus Inc. | $10.28 | 38.48 | $874.79 M | — | 10.76% | 13.17% | $10.76 / $5.81 | $2.74 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 59.9 M | 60.08 M | 56.66 M | 48.56 M | 49.41 M | — |
| Operating Profit | -9.77 M | 1.91 M | 1.67 M | -1.66 M | 2.02 M | — |
| Net Profit | -13.16 M | 0.71 M | 0.58 M | -3.83 M | 0.45 M | — |
| EPS in Rs | -0.25 | 0.01 | 0.01 | -0.07 | 0.01 | -0.04 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 225.21 M | 187.34 M | 159.01 M | 138.58 M |
| Operating Profit | -7.85 M | -3.29 M | -21.46 M | -29.71 M |
| Net Profit | -15.7 M | -9.96 M | -21.72 M | -28.95 M |
| EPS in Rs | -0.3 | -0.19 | -0.42 | -0.56 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 221.69 M | 203.73 M | 196.83 M | 195.39 M |
| Total Liabilities | 92.84 M | 99.82 M | 101.16 M | 94.39 M |
| Equity | 128.85 M | 103.91 M | 95.67 M | 101 M |
| Current Assets | 120.42 M | 99.22 M | 88 M | 98.08 M |
| Current Liabilities | 23.56 M | 30.61 M | 30.43 M | 23.75 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 0.81 M | 4.54 M | -5.72 M | -16.07 M |
| Investing CF | -5.32 M | -10.3 M | 19.25 M | -3.2 M |
| Financing CF | 10.5 M | 2.29 M | 1.95 M | 1.79 M |
| Free CF | -4.78 M | 0.01 M | -20.63 M | -37.32 M |
| Capex | -5.59 M | -4.52 M | -14.92 M | -21.25 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 20.21% | 17.81% | 14.74% | — |
| Earnings Growth % | -57.6% | 54.12% | 24.98% | — |
| Profit Margin % | -6.97% | -5.32% | -13.66% | -20.89% |
| Operating Margin % | -3.49% | -1.75% | -13.5% | -21.44% |
| Gross Margin % | 74.31% | 75.79% | 76.64% | 78.51% |
| EBITDA Margin % | 0.23% | 3.24% | -8.38% | -16.94% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.